TIDMCREO

RNS Number : 4703X

Creo Medical Group PLC

24 November 2017

Creo Medical Group plc

("Creo" or "the Company")

Annual Reports and Accounts and Notice of Annual General Meeting

Chepstow, South Wales - 24 November 2017 - Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, today announces that its Annual Report and Accounts for the year ended 30 June 2017 together with its Notice of Annual General Meeting (AGM) have been sent to shareholders. These documents are available on the Company's website: http://investors.creomedical.com.

The AGM will be held at 10 am on Wednesday 20 December 2017 at the Company's registered office, Block B, Beaufort Park, Chepstow, Wales NP16 5TY.

 
 Contacts 
 Creo Medical:                        Cenkos:                 FTI Consulting: 
 Richard Rees                         Camilla Hume/Mark       Brett Pollard 
  +44 (0)129 160                       Connelly (NOMAD)        / Mo Noonan 
  6005 richard.rees@creomedical.com    Michael Johnson /       +44 (0)203 727 
                                       Russell Kerr (Sales)    1000 
                                       +44 (0)207 397 8900     creo@fticonsulting.com

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, www.creomedical.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOAUSSRRBBAAUAA

(END) Dow Jones Newswires

November 24, 2017 05:49 ET (10:49 GMT)

Creo Medical (LSE:CREO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Creo Medical Charts.
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Creo Medical Charts.